Compare Synopsys, Inc. (SNPS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Synopsys, Inc. trades at $474.63 (market cap $94.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Synopsys, Inc. is far larger — about 12.6× Spyre Therapeutics Inc. Common Stock's market cap, and Synopsys, Inc. is more actively traded (2,520,237 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SNPS | SYRE | |
|---|---|---|
Market Cap | $94.77B | $7.52B |
Volume | 2,520,237 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $534.56 | $108.92 |
52-Week Low | $367.70 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $102.00B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $479.93, down 4.49% today but remains in a strong technical uptrend with bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5% and maintains strong profitability with 72.38% gross margins. Recent investor day announcements highlighted transformative AI partnerships with OpenAI and Amazon, driving positive sentiment and analyst upgrades.
Outlook remains positive with 93% analyst buy ratings and $575.93 consensus target offering 20% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks involve execution challenges and premium valuation at 86.3 P/E. The stock presents a compelling growth story but requires monitoring of integration progress and competitive pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
